Join us for a high-impact Strategic Investor Spotlight with Astellas Pharma, a global pharmaceutical company headquartered in Tokyo, Japan, conducting business in more than 70 countries. Astellas is committed to turning innovative science into value for patients through transformative therapies in oncology, ophthalmology, urology, immunology, and women’s health – and is known for its strong focus on collaboration.
Hear from Arun Bhatia, Commercial Strategy Lead – Digital Health, RX+ Business Accelerator, as he shares insights into Astellas’ investment focus, therapeutic areas of interest, and approach to partnering with early-stage innovators. Arun supports product concept development and leads early commercial and partnership strategy for integrated chronic care management solutions.
This exclusive event includes a short program and a networking session with refreshments, offering Washington state startups and researchers a unique opportunity to learn more about how to engage with Astellas.
About Astellas:
Astellas is advancing innovation through its Focus Area Approach, designed to identify opportunities for the continuous creation of new drugs by focusing on both biology and modality. Beyond its foundational prescription drug portfolio, the company is pioneering Rx+® healthcare solutions that combine its pharmaceutical expertise with cutting-edge technology in partnership with external collaborators. With 18 R&D sites and more than 10 manufacturing facilities worldwide, including cell and gene therapy capabilities, Astellas is driving progress across multiple therapeutic areas. Recent investments, such as the new West Coast Innovation Center in South San Francisco and the Life Sciences Center in Cambridge, Massachusetts, further strengthen its commitment to accelerating the discovery of breakthrough therapies.
Agenda:
3:45 Doors open for registration
4:00 Introduction
4:05 Astellas Company Investment presentation
4:35 Q&A
4:50 Informal networking